All stock reports

GEMAROMA evidence report

Evidence date: 2026-10-01. Research observations only.

What can I do with this stock?

Evaluated 2026-10-02T01:37:53.224812+00:00. Closed-session evidence: 2026-10-01. This is a timestamped assessment, not a live trading feed.

Strategy evidence, instrument feasibility and portfolio suitability are separate. Portfolio suitability has not been assessed.

Today: intraday

Evidence unavailable

No current intraday signal and observed quote supplied; daily bars cannot establish a live setup.

  • No current intraday signal and observed quote supplied; daily bars cannot establish a live setup.

Next week: five trading sessions

No qualifying opportunity

No candidate with a primary five-session horizon in the coherent source run.

  • No candidate with a primary five-session horizon in the coherent source run.

Long term: one to three years

Research only

A financial screen alone does not establish an investment recommendation.

  • A current, source-backed thesis and valuation review is required.

Investment evidence

Statement coverage
FULL_STATEMENTS
Financial source retrieved
2026-09-08T23:41:09.114207+00:00

Metrics

latest_annual_period
2026-03-31
revenue
3664730000.0
net_income
14250000.0
operating_cash_flow
173550000.0
free_cash_flow
-777510000.0
total_assets
6418860000.0
total_liabilities
1919520000.0
total_equity
4499340000.0
cash
159420000.0
total_debt
1518470000.0
revenue_growth
-0.25953681777404203
earnings_growth
1.2833212277249997
net_margin
0.0038884174277504756
roe
0.003167131179239622
debt_to_equity
0.3374872759115781
cash_conversion
12.178947368421053
free_cash_flow_margin
-0.2121602410000191
trailing_pe
Not supplied
forward_pe
Not supplied
peg_ratio
Not supplied
price_to_book
Not supplied
dividend_yield
Not supplied

Other positional research

Research only

1 opportunity assessments; compare evidence and conditions below.

Price Dislocation

Research only. Direction: LONG.

Flags large price dislocations for research without asserting unsupported fundamental quality

  • No active, unexpired validation authority for this exact strategy and horizon.
  • A source-backed entry, invalidation, exit and cost plan is not supplied.
Eligible expression
None selected
Expression comparison
No eligible instrument selected.
Invalidation
Continued price deterioration or adverse fundamental evidence
Entry rule
Not supplied
Entry range (INR)
Not supplied
Exit / review rule
Not supplied
Planned exit
Not supplied
Plan valid until
Not supplied
Promotion reference
Not supplied
Instrument scenarios in INR; quantities are illustrative, not personal sizing
InstrumentEvidence statusContractQuantityCapital / marginTarget P&L after costsStop-level scenario P&LStress lossConditions and limitations
NO_POSITIONAvailableNot suppliedNot suppliedNot supplied0.000.00Not suppliedNo new position; incremental trading P&L is zero.
CASHUnavailableNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedObserved contract, quote and cost evidence not supplied.
FUTURESUnavailableNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedObserved contract, quote and cost evidence not supplied.
OPTIONSUnavailableNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedObserved contract, quote and cost evidence not supplied.
  • No reader capital or loss budget supplied
Decision provenance and limitations
Decision ID
decision-418193c37cf43c4e4030d55fb283a40621b07b26717e0d5ba3ab66e83dc2a958
Policy
stock-decisions-v1
Evidence bundle hash
e3a8f4d7945d490084a9ab3fab2544a3f8f0e4aa3ddf6d4c6fd8a13f5ae3004b
  • market-brief: a7de4d64fedac164d48cdfb9b4081a4666d7f797f7d9c58da304b329b3a61d3c
  • validation-registry: b1069587129bfc64a703cdf8322d0294692585b7d67f5472593e4164bbb0c3bc
  • financial-statements: 41c793b06fc64c18681d05ea6870cdf79ef4baed1c218826206139f3111c773b
  • daily-price: 71f8f7ce265af2b3795ae3e69903b179ff714213e21f7229e2a15ae24eb95607
  • Conditional research decisions are not orders or personalized position sizes.
  • Scenario payoffs are assumptions, not probabilities or expected returns.
  • A stop price does not guarantee a maximum loss through a gap or illiquidity.

Download the decision evidence as JSON

Evidence briefing

The local language model selected and grouped the following supplied facts.

Overview

Price source verification: VERIFIED. The trailing 5-session price return was 0.06%. The trailing 20-session price return was -5.42%. The trailing 60-session price return was -23.74%. The trailing 250-session price return was -38.87%. Average cached traded value over twenty sessions was INR 13,845,975.

Risks

The closing price was -40.08% below its highest close in the available trailing year. The cached financial metric revenue growth is -0.25953681777404203. The cached financial metric net margin is 0.0038884174277504756. The cached financial metric roe is 0.003167131179239622. The cached financial metric free cash flow margin is -0.2121602410000191.

Follow Up

Historical observations do not establish future returns. No verified current news or catalyst evidence is supplied.

Cached observations and evidence limits